Future double-blinded clinical trials may investigate whether the improvement in ME/CFS clinical presentation during low-dose naltrexone treatment is correlated with the restoration of TRPM3 function, Ca2+ re-establishment, and improved clinical manifestations. Here, TRPM3 is linked to myalgic encephalomeyelitis/chronic fatigue syndrome.